Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Neoplasms 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 14Nivolumab 6Carboplatin 5sargramostim 4Fluorouracil 4Drug Therapy 4Thiotepa 3Sorafenib 3Radiotherapy 3Ipilimumab 3Interferon-alpha 3Gemcitabine 3Filgrastim 3Counseling 3Cetuximab 3liposomal doxorubicin 2ixabepilone 2entinostat 2cemiplimab 2belinostat 2atezolizumab 2Temozolomide 2Surveys and Questionnaires 2Sirolimus 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Paclitaxel 2Methods 2Melphalan 2Irinotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × Dacarbazine × Gastrointestinal × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡